- Current report filing (8-K)
August 09 2012 - 4:35PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of
1934
Date of Report (Date of earliest event reported) August 3, 2012
CORTEX PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
1-16467
|
|
33-0303583
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S Employer
Identification No.)
|
|
|
7700 Irvine Center Drive, Suite 750
Irvine, California
|
|
92618
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (949) 727-3157
N/A
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
|
Effective August 3, 2012, Moogak Hwang, Ph.D. was elected as a member of the Board of Directors of
Cortex Pharmaceuticals, Inc. (the Company). Dr. Hwang currently serves as the General Manager of the Department of New Business Development for Samyang Optics Co., Ltd. of Korea (Samyang), which beneficially owns
approximately 24% of the Companys common stock. Dr. Hwangs appointment follows the June 2012 private placement (the Private Placement) with Samyang, which included the Companys issuance to Samyang of a secured
promissory note in the principal amount of (Won)465,000,000 (South Korean Won), representing approximately $400,000 USD, and warrants to purchase up to 4,000,000 shares of the Companys common stock, as more fully described in the
Companys Current Report on Form 8-K, filed with the Securities and Exchange Commission on June 27, 2012 and incorporated by reference herein.
Pursuant to the Private Placement, Samyang became entitled to designate a representative to serve as a member of the Board of Directors of the Company. Dr. Hwang is Samyangs designee and
representative on the Board of Directors.
Dr. Hwang has served as the General Manager of the Department of New Business
Development at Samyang since 2009. Prior to that time, during 2008 and 2009 he was a researcher at the National Cancer Center of Korea. Dr. Hwang obtained his Ph.D. in Biology from Yonsei University of Korea in 2008 and his M.S. in Biology from
the same university in 2001. He obtained a B.S. in Microbiology from Ulsan University of Korea during 1998.
In addition to
the Private Placement, the Company previously completed and reported a private placement of $1.5 million in principal amount of a convertible promissory note and related warrants with Samyang in January 2010 and a private placement of $0.5 million
in unregistered shares of common stock and related warrants with Samyang Value Partners Co., Ltd., a wholly owned subsidiary of Samyang, in October 2011.
Concurrently with the October 2011 private placement, Samyang and the Company entered into a license agreement for rights to the AMPAKINE CX1739 for the treatment of neurodegenerative diseases in South
Korea. The license agreement also provides Samyang with rights of negotiation to expand its territory into other Southeast Asian countries, excluding Japan, Taiwan and China, and to include rights to the high impact AMPAKINE CX1846 as a potential
treatment for neurodegenerative diseases. Concurrently with the Private Placement, the license agreement with Samyang was amended to include rights to the AMPAKINE CX1739 in South Korea for the treatment of sleep apnea and respiratory depression and
to modify certain payment terms and other obligations.
Other than as described above, there are no existing or currently
proposed transactions to which the Company is a party in which Samyang or Dr. HWang has a direct or indirect interest.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CORTEX PHARMACEUTICALS, INC.
|
|
|
|
|
Date: August 9, 2012
|
|
|
|
By:
|
|
/s/ Maria S. Messinger
|
|
|
|
|
|
|
Maria S. Messinger
|
|
|
|
|
|
|
Vice President, Chief Financial Officer and Corporate Secretary
|
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jul 2023 to Jul 2024